Xenograft are the cells of one species transplanted to another species.
A team led by researchers at Weill Cornell Medicine and Children's National Hospital has developed a unique pre-clinical model that enables the study of long-term HIV infection, and the testing of new therapies aimed at curing the disease.
Leukemias are debilitating cancers of the hematopoietic or blood-forming cells of the bone marrow. Now, researchers at Tokyo Medical and Dental University describe an ingenious strategy against chronic myelomonocytic leukemia (CMML) wherein an antibody-drug conjugate (ADC) comprising a cytotoxic drug payload linked to an antibody that selectively targets specific cell lines effectively blocks malignant cell proliferation at source.
Scientists at Urology Research Laboratory of the Department for BioMedical Research, University of Bern and Urology Department of the Inselspital of Bern, have established organoid culture models from prostate tumor biopsies.
Invasive lobular carcinoma (ILC) is a type of breast cancer that begins in the milk-producing glands (lobules) of the breast.
Several treatments for cancer have been devised by science, but unfortunately none of them are completely efficient or foolproof.
Cancer is a major, worldwide challenge, and its impact is projected to escalate due to aging and growth of the population.
Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer.
A new study by researchers in Cleveland Clinic's Taussig Cancer Institute and Lerner Research Institute describes a novel class of targeted cancer drugs that may prove effective in treating certain common types of leukemia.
The observance of Lung Cancer Awareness Month in November affords an opportunity to take stock of current approaches to lung cancer research, and to cancer research more widely.
Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.
The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21.
The cover for issue 36 of Oncotarget features, "Knockdown of APOBEC3B is associated with a lower tumor growth in an adrenocortical carcinoma xenograft mouse model," by Gara, et al. which reported that the role of APOBEC3B in adrenocortical carcinoma and the mechanisms through which its expression is regulated in cancer are not fully understood.
Professor Deborah Goberdhan speaks to News-Medical about her team's latest research into cancer cells, and the mechanisms they use to communicate.
Immunotherapies for cancer -; treatments that prime the immune system to attack tumors -; are valuable weapons in the anti-cancer arsenal. But some cancers are more difficult to target with this strategy than others.
The enzyme serine palmitoyl-transferase can be used as a metabolically responsive "switch" that decreases tumor growth, according to a new study by a team of San Diego scientists, who published their findings Aug. 12 in the journal Nature.
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of the Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.
Computational modeling has provided new insights into the heart's vascular system, a complex and mechanically demanding system that remains poorly understood.
Precision medicine in cancer treatment uses genetic changes in the cancer cells to select the best therapies for individual patients.
With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of "synthetic lethality," exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the survival of cancer cells.
Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).